Vor Bio Appoints Telitacicept Development Expert Dr. Qing Zuraw as Chief Development Officer
核心洞察
Vor Bio (搜索) has appointed Dr. Qing Zuraw as Chief Development Officer, bringing over 25 years of experience in autoimmune disease clinical development.
Dr. Zuraw previously led telitacicept development at RemeGen across four indications, achieving regulatory approvals in China for SLE, generalized myasthenia gravis, and rheumatoid arthritis.
The appointment positions Vor Bio (搜索) to advance telitacicept through Phase 3 clinical development and global commercialization for autoantibody-driven conditions.
Vor Bio (搜索) has appointed Dr. Qing Zuraw as Chief Development Officer, effective immediately, bringing extensive experience with telitacicept development to the clinical-stage biotechnology company as it advances its autoimmune disease pipeline. Dr. Zuraw joins from RemeGen Co., Ltd., where she led the successful clinical development of telitacicept across four key autoimmune indications, resulting in multiple regulatory approvals in China.
Proven Track Record with Telitacicept Development
Dr. Zuraw brings over 25 years of experience leading complex global and U.S. clinical development programs across autoimmune, inflammatory, and immunologic diseases. At RemeGen, she served as Chief Development Officer and Head of Global Clinical Development for Autoimmune Diseases, where she was instrumental in the successful development and execution of clinical trials for telitacicept across systemic lupus erythematosus (SLE), Sjögren's syndrome, myasthenia gravis (MG), and rheumatoid arthritis (RA).
Her leadership culminated in regulatory approvals in China for the treatment of SLE, generalized MG, and RA. At RemeGen, Dr. Zuraw built and led a cross-functional global team that managed all aspects of telitacicept development, including clinical trial design, regulatory strategy, site engagement, and execution.
Regulatory Expertise and FDA Designations
Dr. Zuraw played a central role in regulatory interactions with the U.S. Food & Drug Administration, European Medicines Agency, and China's Center for Drug Evaluation. Her efforts resulted in achieving Fast Track, Breakthrough Therapy, and Orphan Drug designations for telitacicept across multiple indications.
"We are delighted to welcome Qing to Vor Bio (搜索) at a critical time for the company," said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of the Board. "Her deep and diverse clinical development expertise across autoimmune and immunological diseases and with telitacicept will be invaluable as we execute on our late-stage programs. Qing's ability to lead high-performing clinical organizations will be instrumental as we drive forward our global development programs, particularly in the U.S."
Extensive Industry Experience
Prior to RemeGen, Dr. Zuraw held senior leadership roles at Janssen Research & Development (搜索), Teva Pharmaceutical Industries (搜索) Ltd., Akebia Therapeutics, Inc., Biogen Inc., and Covance, Inc., where she led global clinical development programs across rheumatology, nephrology, respiratory, and immunology. She played a key role in the U.S. FDA approval of Guselkumab for psoriatic arthritis and contributed to multiple NDA and BLA submissions across therapeutic areas.
Strategic Focus on Global Telitacicept Development
"Vor Bio (搜索) is uniquely positioned to become a leader in autoimmune therapeutics," said Dr. Zuraw. "Having been intimately involved in the development of telitacicept in China from early clinical stages through to multiple approvals, I'm thrilled to join the talented team at Vor Bio to bring telitacicept to patients globally."
Vor Bio (搜索) is focused on rapidly advancing telitacicept, described as a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide. The company positions itself as transforming the treatment of autoimmune diseases through this therapeutic approach.